Skip to Content

Clinical Trials

Chronic Myelogenous Leukemia (CML)

  • 2008-0087: Azacitidine maintenance therapy after allogeneic stem cell transplantation for CML
  • 2005-0508: Alloreactive NK Cells with Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for AML and MDS
  • 2007-0772: G-CSF & Plerixafor with Busulfan/ Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias
  • 2006-0200: Busulfan-Fludarabine-elofarabine with allogeneic stem cell transplantation for advanced refractory Acute Myeloid Leukemia 
  • 2008-0227: Multi-institutional Trial of Allo SCT for Hematologic Malignancies followed by Post-transplant Immunosuppression with High-dose Cyclophosphamide.
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
  • 2006-0075: Infusion of Expanded Cord Blood T cells following Cord Blood Transplantation

Acute Myelogenous Leukemia / Myelodysplastic Syndrome

  • 2005-0366: A randomized study of once daily IV Busulfan/ Fludarabine with SCT for AML and MDS 
  • 2005-0508: Alloreactive NK Cells with Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation
  • 2006-0553: Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients Undergoing Allogeneic Transplant
  • 2005-0695: Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following Selected Peripheral Blood Stem Cell Transplant From A Haploidentical Donor 
  • 2008-0227: Multi-institutional Trial of Allo SCT for Hematologic Malignancies followed by Post-transplant Immunosuppression with High-dose Cyclophosphamide.
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
  • 2005-0617: PR 1 Antigen-Specific Cytotoxic T Lymphocytes (PR l-CTLl For Treatment of AML/MDS after Allogeneic CD34-Selected Cell Transplantation
  • 2007-0772: G-CSF & Plerixafor with Busulfan/ Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias
  • 2006-0200: Busulfan-Fludarabine-Clofarabine with Allogeneic Stem Cell transplantation for advanced refractory Acute Myeloid Leukemia 
  • 2008-0261: Busulfan (IV) and Fludarabine followed by post-Allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in patients with hematologic malignancies
  • 2005-0781: Cord Blood Expansion on Mesenchymal Stem Cells if no related or unrelated donor

Acute Lymphocytic Leukemia (ALL)

  • 2004-0190: Busulfan plus Melphalan conditioning regimen for lymphoid malignancies
  • 2006-0553: Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients with Advanced Hematologic Malignancies undergoing Allogeneic Transplant
  • 2008-0261: Busulfan (IV) and Fludarabine followed by post-allogeneic transplantation Cyclosphosphamide for Graft-versus-Host Disease Prophylaxis in patients with hematologic malignancies 
  • 2008-0227: Multi-institutional Trial of Allo SCT for Hematologic Malignancies followed by Post-transplant Immunosuppression with High-dose Cyclophosphamide
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
  • 2005-0695: Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following Selected Peripheral Blood Stem Cell Transplant From A Haploidentical Donor
  • 2005-0781: Cord Blood Expansion on Mesenchymal Stem Cells if no related or unrelated donor

Chronic Lymphocytic Leukemia (CLL)

  • 2007-0871: Nonmyeloablative Stem Cell Transplantation with or without Revlimid for eligible patients with related or unrelated donor ISSA KHOURIfor Chronic lymphocytic leukemia ikhouri@mdanderson.org
  • ID0l-233: Safety and Efficacy of IDEC-Y2B8 in Nonmyeloablative Transplantation For lymphoma and CLL patients
  • 2008-0210: Trial of immune reconstitution with CD3/CD28 bead activated T-cells following chemo-immunotherapy
  • 2008-0227: Multi-institutional Trial of Allo SCT for Hematologic Malignancies followed by Post-transplant Immunosuppression with High-dose Cyclophosphamide 
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
  • 2008-0246: Fludarabine, Bendamustine and bendamustine (FBR) Allogeneic Conditioning
  • 2006-0066: Bortezomib (Velcade) and Allogeneic Non-Myeloablative Blood Stem Cell or Bone Marrow Transplantation for Patients with Indolent Lymphoid Malignancies
  • ID02-407: Randomized Trial: Unmanipulated vs Expanded CB For pts lacking a related or unrelated donor

Myeloproliferative Disease (MPD)

  • 2005-0726: Allogeneic SCT for myelofibrosis using reduced intensity busulfan and fludarabine conditioning secondary to Polycythemia Vera or Essential Thrombocythemia
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
  • 2008-0261: Busulfan (IV) and Fludarabine followed by post-allogeneic transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in patients with hematologic malignancies
  • 2008-0227: Multi-institutional Trial of Allo SCT for Hematologic Malignancies followed by Post-transplant High risk Immunosuppression with High-dose Cyclophosphamide.

Myeloma / Amyloidosis

  • 2005-0601: Randomized Ph II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients with Multiple Myeloma or Amyloidosis 
  • IDOl-518: Fluda/Melphalan 140 vs Fluda/Melphalan 100 Allo Transp. followed By Allo PBSC or BM Transplant 
  • 2008-0261: Busulfan (IV) and Fludarabine followed by post-allogeneic transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis 
  • 2006-0553: Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic regimen
  • 2006-0803: Gemcitabine combined with busuWan and melphalan, with hematopoietic cell transplantation, for patients with poor-prognosis advanced lymphoid malignancies 
  • 2008-0227: Multi-institutional Trial of Allo SCT for Hematologic Malignancies followed by Post-transplant High risk Immunosuppression with High-dose Cyclophosphamide.
  • 2004-0660: ID-specific donor vaccinated lymphocyte infusion pts with MM relapsing or failing to achieve CR post transplant
  • 2005-0781: Cord Blood Expansion on Mesenchymal Stem Cells if no related or unrelated donor
  • 2008-0329: Evaluation of Lenalidomide as Maintenance Therapy post Allogeneic Hematopietic Cell Transplantation for High-Risk Multiple Myeloma
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies

Lymphoma: Hodgkin's Disease 

  • 2005-0015: Reduced-intensity allogeneic stem cell transplantation followed by adoptive immunotherapy 
  • 2006-0553: Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Transplant
  • 2006-0803: Gemcitabine combined with busuWan and melphalan, with hematopoietic cell transplantation
  • 2008-0261: Busulfan (IV) and Fludarabine followed by post-allogeneic transplantation Cyclosphosphamide for Graft-versus-Host Disease 
  • 2008-0227: Multi-institutional Trial of Allo SCT for Hematologic Malignancies followed by Post-transplant Immunosuppression with High-dose Cyclophosphamide
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies 
  • 2005-0781: Cord Blood Expansion on Mesenchymal Stem Cells If no related or unrelated donor

Diffuse Large Cell Lymphoma

  • 2006-1018: Zevalin/BEAM/Rituximab vs BEAM/Rituximab with or without Rituximab Maintenance in Autologous Stem Cell Transplantation 
  • 2004-0271: Randomized trial of standard vs. HD Rituximab in addition to auto transplantation with BEAM 
  • 2007-0483: CT-2007-01: Ph II Safety and Efficacy Study of the Monoclonal Antibody CT-0ll For patients eligible for Auto Transplant in Patients with Diffuse Large B-Cell Lymphoma following Auto SCT 
  • 2006-0066: Bortezomib (Velcade) and Allogeneic Non-Myeloablative Blood Stem Cell or Bone Marrow Transplantation for Patients with Indolent Lymphoid Malignancies
  • 2005-0781: Cord Blood Expansion on Mesenchymal Stem Cells if no related or unrelated donor
  • ID02-407:  Unmanipulated vs Expanded CB For pts lacking a related or unrelated donor
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies

Follicular Lymphoma 

  • ID0l-233: Safety and Efficacy of IDEC-Y2B8 in Nonmyeloablative Transplantation 
  • 2008-0246: Fludarabine, Bendamustine and bendamustine (FBR) Non-myeloablative Allogeneic Conditioning
  • 2006-0803: Gemcitabine combined with busulfan and melphalan, with hematopoietic cell transplantation
  • 2005-0234: Immunotherapy with NK cell, Rituximab and rhu-GMCSF in Non-myeloablative Allogeneic Stem Cell Transplantation
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies

T-Cell Lymphoma

  • ID02-645: Autologous And Allogeneic Transplantation With Campath
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies

Cutaneous T-Cell Lymphoma

  • DM03-0279: Study of Allogeneic Transplantation in Patients with Cutaneous T-Cell Lymphoma
  • 2008-0363: Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies

Breast Cancer

  • 2006-0873: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Bevacizumab for Advanced Solid Tumor

Ovarian Cancer

  • 2007-0368: Bevacizumab/Gemcitabine/Docetaxel/Melphalan/Carboplatin for Ovarian Cancer
  • 2008-0378: High-dose chemotherapy for poor-prognosis relapsed germ-cell tumors

Germ Cell Tumors

  • 2008-0378: High-dose chemotherapy for poor-prognosis relapsed germ-cell tumors

Auto-Immune Disease

  • 2004-0721: Randomized, Open-Label, Ph II/III Multicenter Study of HD Immunosuppressive Tx Using TBI, Cy, ATGAM, and Autologous Transp w Auto-CD34+HPC vs lV Pulse Cy for the Treatment of Severe Systemic Sclerosis
  • 2006-0018: Ph II Study of HD Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin, and CD34+ SC Transplant for the Treatment of Poor Prognosis Multiple Sclerosis

Aplastic Anemia

  • 2005-0513: Fludarabine-based conditioning for allogeneic marrow transplantation from HLA-compatible unrelated donors in severe aplastic anemia

Neuroblastoma

  • 2006-0752: Study to Infuse Haploidentical Natural Killer Cells in Patients with Relapsed Neuroblastoma
  • 2006-0374: Autologous Stem Cell Rescue with CD133+Selected Hematopoietic Progenitor Cells in Patients with High-risk Neuroblastoma
  • 2007-0028: PBMTC ONC-032; High dose Temozolomide,Thiotepa, and Carboplatin with Autologous Stem Cell Rescue (ASCR) followed by continuous therapy with 13-cis-retinoic acid in patients with recurrent/refractory malignancies

© 2014 The University of Texas MD Anderson Cancer Center